Best Open Access Pharmacogenomics Journals
Pharmacogenomics is that the study of the role of the ordering in drug response. Its name (pharmaco- + genetics) reflects it’s combining of pharmacological medicine and genomics.
Pharmacogenomics analyzes however the genetic makeup of a personal affects his/her response to medication. It deals with the influence of noninheritable and genetic genetic variation on drug response in patients by correlating organic phenomenon or single-nucleotide polymorphisms with materia medica (drug absorption, distribution, metabolism, and elimination) and pharmacodynamics (effects mediate through a drug's biological targets). The term
pharmacogenomics is commonly used interchangeably with genetics. though each terms relate to drug response supported genetic influences,
genetics focuses on single drug-gene interactions, whereas
pharmacogenomics encompasses a a lot of genome-wide association approach, incorporating
genetics and epigenetics whereas addressing the results of multiple genes on drug response.
Pharmacogenomics aims to develop rational means that to optimize drug medical care, with relevance the patients' genotype, to make sure most potency with lowest adverse effects. Through the employment of pharmacogenomics, it's hoped that pharmaceutical drug treatments will deviate from what's dubbed because the "one-dose-fits-all" approach.
Pharmacogenomics additionally tries to eliminate the trial-and-error methodology of prescribing, permitting physicians to require into thought their patient's genes, the practicality of those genes, and the way this could have an effect on the efficaciousness of the patient's current or future treatments (and wherever applicable, offer a proof for the failure of past treatments).
High Impact List of Articles
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Lindsay A Renfro, Sumithra J Mandrekar
Editorial: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
-
Maintenance treatment of multiple myeloma: evidence from recent clinical trials
Donna E Reece
Review Article: Clinical Investigation
Relevant Topics in Clinical